BD Restructures Connected Care Segment, Appoints Industry Veteran as President
BD (Becton, Dickinson and Company) has announced a significant restructuring of its connected care segment, appointing former Masimo executive Bilal Muhsin as president of the newly consolidated unit. This move marks a crucial step in BD's ongoing transformation strategy, as the company aims to strengthen its position as a leading pure-play MedTech innovator.
Leadership Transition and Strategic Realignment
Bilal Muhsin, who most recently served as Chief Operating Officer at Masimo, brings over 25 years of experience in connected care technologies, software, and informatics strategies to his new role at BD. Effective July 2, 2025, Muhsin will lead the company's efforts in artificial intelligence, analytics, medication management, workflow robotics, and advanced patient monitoring.
Tom Polen, CEO of BD, emphasized the strategic importance of this appointment, stating, "Bilal will have a profound impact at BD as we advance our connected care strategy with cutting-edge, AI-driven technology that transforms patient care by improving safety, efficiency, and outcomes."
Consolidation of Connected Care Technologies
The restructured connected care segment will integrate several key technologies and product lines:
- Artificial intelligence and analytics capabilities
- Medication management systems, including the Pyxis line of automated dispensing systems
- Workflow robotics solutions
- Advanced patient monitoring devices, such as the Alaris infusion pumps
This consolidation aligns with BD's "New BD" strategy, which focuses on medical essentials and aims to achieve annual revenue growth of 5.5% or more. The company's recent acquisitions, including the $1.53 billion buyout of Parata Systems and the $93 million acquisition of Medkeeper, have bolstered its pharmacy robotics business and complement the existing Pyxis franchise.
Industry Implications and Future Outlook
BD's restructuring comes at a critical time for the company and the broader MedTech industry. The Pyxis business, which received a warning letter from the FDA in 2024, is entering a pivotal period with the recent launch of a new device. Polen has indicated that this launch could lead to market share shifts and pricing premiums.
As BD continues to execute its transformation plan, the company is also considering options for its diagnostic and biosciences divisions, which generated approximately $3.4 billion in revenue in 2024. The board of directors is exploring potential spinoffs or sales, with more details expected to be announced by the end of September 2025.
References
- BD taps Masimo exec to lead restructured connected care group
The to-be-consolidated unit will harbor BD’s AI work as well as its devices for medication management and patient monitoring. Bilal Muhsin will serve as its president.
- BD appoints Bilal Muhsin as president of new connected care group
The former Masimo executive will lead strategy development to support the transition to BD’s revised business structure over the next several months.
Explore Further
What has been Bilal Muhsin's previous impact on connected care technologies at Masimo?
How has BD's performance been in terms of revenue growth since initiating the 'New BD' strategy?
What specific challenges did the Pyxis line face that resulted in the FDA warning letter in 2024?
Are there any recent personnel changes among BD's competitors that reflect a similar strategic realignment?
What past experiences does Bilal Muhsin have in implementing artificial intelligence and analytics strategies within the MedTech industry?